结直肠癌免疫疗法
Colorectal cancer immunotherapy.
作者信息
Xiang Bo, Snook Adam E, Magee Michael S, Waldman Scott A
机构信息
Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
出版信息
Discov Med. 2013 May;15(84):301-8.
Abstract
Antitumor immunotherapy for colorectal cancer has been studied at the bench and bedside for decades. Some clinical trials of cancer immunotherapy have demonstrated a potential benefit for patients with colorectal cancer, yet immunotherapy remains only an experimental option for this disease. Here, we review the major immunotherapeutic approaches currently under investigation for colorectal cancer, including cancer vaccines and adoptive cell therapy. Weakness and advantages of each strategy and progress in clinical trials will be described. Examination of previous and ongoing research in colorectal cancer therapy should define a path towards identification, approval, and mainstream adoption of colorectal cancer immunotherapeutics.
摘要
几十年来，针对结直肠癌的抗肿瘤免疫疗法一直在实验室和临床进行研究。一些癌症免疫疗法的临床试验已证明对结直肠癌患者有潜在益处，但免疫疗法对这种疾病而言仍只是一种实验性选择。在此，我们综述了目前正在研究的针对结直肠癌的主要免疫治疗方法，包括癌症疫苗和过继性细胞疗法。将描述每种策略的优缺点以及临床试验的进展。对结直肠癌治疗方面既往和正在进行的研究进行审视，应能确定一条通向结直肠癌免疫治疗药物的识别、批准及广泛应用的道路。
相似文献
1
Colorectal cancer immunotherapy.
Discov Med. 2013 May;15(84):301-8.
2
Immunotherapy for metastatic colorectal cancer: present status and new options.
Scand J Gastroenterol. 2012 Mar;47(3):315-24. doi: 10.3109/00365521.2012.640831. Epub 2012 Jan 3.
3
Immunotherapy for colorectal cancer.
Am J Surg. 1999 Apr;177(4):344-8. doi: 10.1016/s0002-9610(99)00051-3.
4
Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer.
Dis Markers. 2022 Feb 15;2022:8270305. doi: 10.1155/2022/8270305. eCollection 2022.
5
Review on the immunotherapy strategies against metastatic colorectal carcinoma.
Immunotherapy. 2016 Oct;8(10):1245-61. doi: 10.2217/imt-2016-0045.
6
[Immunotherapy for colorectal cancer].
Bull Cancer. 2013 Sep;100(9):871-85. doi: 10.1684/bdc.2013.1800.
7
Immunotherapy for colorectal cancer.
World J Gastroenterol. 2013 Dec 14;19(46):8531-42. doi: 10.3748/wjg.v19.i46.8531.
8
Immunotherapy for colorectal cancer.
Expert Rev Anticancer Ther. 2003 Feb;3(1):63-78. doi: 10.1586/14737140.3.1.63.
9
Vaccines for colorectal cancer and renal cell carcinoma.
Cancer J. 2011 Sep-Oct;17(5):283-93. doi: 10.1097/PPO.0b013e318232ff44.
10
Vaccines for colorectal cancer.
Trends Mol Med. 2001 Jul;7(7):307-13. doi: 10.1016/s1471-4914(01)01992-x.
引用本文的文献
1
Identification and validation of a novel 17 coagulation-related genes signature for predicting prognostic risk in colorectal cancer.
Heliyon. 2024 Jun 7;10(12):e32687. doi: 10.1016/j.heliyon.2024.e32687. eCollection 2024 Jun 30.
2
DNA damage repair molecular subtype derived immune signature applicable for the prognosis and immunotherapy response prediction in colon cancer.
Transl Cancer Res. 2023 Oct 31;12(10):2781-2805. doi: 10.21037/tcr-23-747. Epub 2023 Oct 17.
3
Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology.
Front Immunol. 2022 Oct 20;13:1027124. doi: 10.3389/fimmu.2022.1027124. eCollection 2022.
4
Effect of lycopene as an adjuvant therapy with 5-florouracil in human colon cancer.
Saudi J Biol Sci. 2022 Sep;29(9):103392. doi: 10.1016/j.sjbs.2022.103392. Epub 2022 Jul 25.
5
LncRNA NEAT1 Promotes the Malignant Progression of Colorectal Cancer by Targeting ZEB1 via miR-448.
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221085348. doi: 10.1177/15330338221085348.
6
Immune responses of patients without cancer recurrence after a cancer vaccine over a long term.
Mol Clin Oncol. 2022 Jun;16(6):112. doi: 10.3892/mco.2022.2545. Epub 2022 May 13.
7
Lymphocytes in tumor-draining lymph nodes co-cultured with autologous tumor cells for adoptive cell therapy.
J Transl Med. 2022 May 23;20(1):241. doi: 10.1186/s12967-022-03444-1.
8
Immunopeptidomic analyses of colorectal cancers with and without microsatellite instability.
Mol Cell Proteomics. 2022 May;21(5):100228. doi: 10.1016/j.mcpro.2022.100228. Epub 2022 Apr 1.
9
Adoptive T-Cell Therapy in Advanced Colorectal Cancer: A Systematic Review.
Oncologist. 2022 Mar 11;27(3):210-219. doi: 10.1093/oncolo/oyab038.
10
Comparison of four methods of colon cancer cell lysates preparation for maturation of dendritic cells.
Res Pharm Sci. 2021 Nov 11;17(1):43-52. doi: 10.4103/1735-5362.329925. eCollection 2022 Feb.
本文引用的文献
1
Peptide Vaccine Therapy in Colorectal Cancer.
Vaccines (Basel). 2012 Aug 24;1(1):1-16. doi: 10.3390/vaccines1010001.
2
Immunomodulatory therapy for melanoma: ipilimumab and beyond.
Clin Dermatol. 2013 Mar-Apr;31(2):191-9. doi: 10.1016/j.clindermatol.2012.08.006.
3
GUCY2C: at the intersection of obesity and cancer.
Trends Endocrinol Metab. 2013 Apr;24(4):165-73. doi: 10.1016/j.tem.2013.01.001. Epub 2013 Jan 29.
4
MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.
Cancer Prev Res (Phila). 2013 Jan;6(1):18-26. doi: 10.1158/1940-6207.CAPR-12-0275. Epub 2012 Dec 17.
5
Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer.
Exp Ther Med. 2011 Jan;2(1):73-79. doi: 10.3892/etm.2010.182. Epub 2010 Dec 2.
6
Adoptive immunotherapy for cancer: harnessing the T cell response.
Nat Rev Immunol. 2012 Mar 22;12(4):269-81. doi: 10.1038/nri3191.
7
Cancer statistics, 2012.
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.
8
GUCY2C-targeted cancer immunotherapy: past, present and future.
Immunol Res. 2011 Dec;51(2-3):161-9. doi: 10.1007/s12026-011-8253-7.
9
Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.
Nat Rev Clin Oncol. 2011 Aug 2;8(10):577-85. doi: 10.1038/nrclinonc.2011.116.
10
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.
Mol Ther. 2011 Mar;19(3):620-6. doi: 10.1038/mt.2010.272. Epub 2010 Dec 14.
Zotero 插件